Improving therapies for Hemophilia B through better protein production techniques
Official title: Safer and more effective FIX therapeutics: impact of codon optimization
Funded at Cleveland State University · NIH-10600842 · Data updated 2026-11-12
This study is working on improving how a key protein for blood clotting is made, which could help create better and safer treatments for people with Hemophilia B.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland State University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | April 1, 2020 |
| Project end | March 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $371,250 |
| NIH project number | 5R01HL151392-04 |
| Project ID | NIH-10600842 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Hemophilia B or those with Factor IX deficiency.
✕Less likely to help
Patients with other types of hemophilia or unrelated bleeding disorders may not benefit from this research.
What this research studies
This research focuses on enhancing the production of Factor IX, a crucial protein for blood clotting, by optimizing the genetic code used to create it. By adjusting the codons, or the building blocks of the genetic code, the researchers aim to increase the efficiency and effectiveness of protein synthesis. This could lead to safer and more effective treatments for patients with Hemophilia B, a genetic disorder that impairs blood clotting. The approach involves advanced genetic techniques to ensure that the proteins produced are both functional and abundant.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with Hemophilia B.
How similar studies have gone: Previous research has shown promise in using codon optimization to enhance protein production, indicating a potential for success in this approach.
Where this research is happening
-
Cleveland State University
Cleveland, United States Active
Researchers
- Principal investigator: Komar, Anton a. — Cleveland State University
- Study coordinator: Komar, Anton a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.